REFERENCES
- Barndorff-Nielsen, O. E. (1991). Modified signed log-likelihood ratio. Biometrika 78:557–563.
- Brazzale, A. R., Davison, A. C., Reid, N. (2007). Applied Asymptotics: Case Studies in Small-Sample Statistics. Cambridge: Cambridge University Press.
- Burzykowski, T., Molenberghs, G., Buyse, M. (2005). The Evaluation of Surrogate Endpoints. New York: Springer.
- Buyse, M., Molenberghs, G. (1998). Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54:1014–1029.
- Chow, S.-C., Liu, J.-P. (2009). Design and Analysis of Bioavailability and Bioequivalence Studies, 3rd ed. Boca Raton, Florida: Chapman & Hall/CRC Press.
- Freedman, L. S., Graubard, B. I., Schatzkin, A. (1992). Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 11:167–178.
- Molenberghs, G., Buyse, M., Burzykowski, T. (2005). The history of surrogate endpoint validation. In The Evaluation of Surrogate Endpoints, Burzykowski, Molenberghs and Buyse, (eds.), 67–82. New York: Springer.
- Prentice, R. L. (1989). Surrogate endpoints in clinical trials: definitions and operational criteria. Statistics in Medicine 8:431–440.